Skip to main content

Advertisement

Table 2 Treatment-related adverse events

From: MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

  No IMP321 N (%) IMP321 N (%) No IMP321 N (%) IMP321 N (%)
Treatment-related event  
Non-hematological Grade 1-2 Grade 3-4
Fatigue 6 (100%) 6 (100%) - -
Nausea/Vomiting 5 (83%) 1 (16.6%) - -
Constipation - - 1 (16.6%) -
Alopecia 6 (100%) 6 (100%) - -
Mucositis (oral) - 1 (16.6%) - -
Weight loss 6 (100%) 6 (100%) - -
Hematological     
Anemia 4 (66.6%) 5 (83%) 1 (16.6%) 1 (16.6%)
Leucopenia - - 6 (100%) 6 (100%)
Trombocitopenia - 4 (66.6%) 4 (66.6%) 2 (33%)
Febrile Neutropenia (grade 3) n/a n/a 2 (33%) 3 (50%)
CD4 Lymphopenia (≥ grade 3) n/a n/a 6 (100%) 6 (100%)